European Commission grants Marketing Authorisation for HyQvia
Baxter and Halozyme Therapeutics announced yesterday that they have received a marketing authorization from the European Commission for HyQvia as a treatment for adults with primary and secondary immunodeficiencies. This follows a positive opinion for the product from the European Medicines Agency’s Committee for Medicinal Products for Human Use earlier this year. For more information, please see the attached press release.
Registration No. 1058005